Clinical Trial Update: Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of obinutuzumab and venetoclax in relapsed or refractory diffuse large B-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Obinutuzumab (obinutuzumab)
• Venetoclax (venetoclax)

Snippet

Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie | Conditions: Lymphoma, Large B-Cell, Diffuse | Phase 2 | Status: COMPLETED